COST-EFFECTIVENESS ANALYSIS IN THE REAL WORLD: THE CASE OF STATINS

REFERENCES

• Boardman A.E., Greenberg D.H., Vining A.R., Weimer D.L. Cost-benefit Analysis: Concepts and Practice. Prentice Hall, Upper Saddle River, NJ 1996; 1–493
   Google Scholar
• Garber A.M., Phelps C.E. Economic Foundations of Cost-effectiveness Analysis. Journal of Health Economics 1997; 16: 1–31
   PubMed Web of Science ®Google Scholar
• Neumann P.J., Johanneson M. From Principle to Public Policy: Using Cost-Effectiveness Analysis. Health Affairs 1994; 13(3)206–215
   Web of Science ®Google Scholar
• Willke R.J. What's All this about Pharmacoeconomics?. Business Economics 1995; 30(2)26–32
   Google Scholar
• McBride S.H. Pharmacoeconomic Studies – Not Always What they Seem. Managed Healthcare 1995; 5(6)S32–S35
   Google Scholar
• Russell L.B., Gold M.R., Siegel J.E., Daniels N., Weinstein M.C. The Role of Cost-effectiveness Analysis in Health and Medicine. Journal of the American Medical Association 1996; 276(14)1172–1177
   PubMed Web of Science ®Google Scholar
• Brown G.C., Sharma S., Brown M.M., Garrett S. Evidence-based Medicine and Cost-effectiveness. Journal of Health Care Finance 1999; 26(2)14–23
   PubMedGoogle Scholar
• Smith M.C., Kolassa E.M., Perkins G., Siecker B. Pharmaceutical Marketing: Principles, Environment, and Practice. Pharmaceutical Products Press, New York 2002; 371
   Google Scholar
• Eastaugh S.R. Health Care Finance: Cost, Productivity, & Strategic Design. Aspen Publishers, Gaithersburg, MD 1998; 1–257
   Google Scholar
• Discounting Health Care: Only a Matter of Timing? [Editorial]. Lancet 1992; 340(8812)148–149
   PubMed Web of Science ®Google Scholar
• Lipscomb J. Time Preferences for Health in Cost-effectiveness Analysis. Medical Care 1989; 27(Supplement)233–253
   PubMedGoogle Scholar
• Cost-effectiveness in Health Care Medicine, M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein. Oxford University Press, New York 1996
   Google Scholar
• Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., Russell L.B. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. Journal of the American Medical Association 1996; 276(15)1253–1258
   PubMed Web of Science ®Google Scholar
• Edelson J.T., Weistein M.C., Tosteson A.N.A., Williams L., Lee T.H., Goldman L. Long-term Cost-effectiveness of Various Initial Monotherapies for Mid to Moderate Hypertension. Journal of the American Medical Association 1990; 263(3)407–413
   PubMed Web of Science ®Google Scholar
• Viscusi W.K. Discounting Health Effects for Medical Decisions. Valuing Health Care: Costs, Benefits, and Effectiveness of Pharmaceuticals and Other Medical Technologies, F.A. Sloan. Cambridge University Press, New York 1996; 125–147
   Google Scholar
• Teutsch S.M., Murray J.F. Dissecting Cost-effectiveness Analysis for Preventive Interventions: A Guide for Decision Makers. American Journal of Managed Care 1999; 5(3)301–305
   PubMed Web of Science ®Google Scholar
• Gevers J. Legal Issues in the Development and Use of Clinical Practice Guidelines. Medicine and Law 2001; 20(2)183–191
   PubMedGoogle Scholar
• Oster G., Borok G.M., Menzin J., Heyse J.F., Epstein R.S., Quinn V., Benson V., Dudl R.J., Epstein A.M. Cholesterol-Reduction Intervention Study (CRIS): A Randomized Trial to Assess Effectiveness and Costs in Clinical Practice. Archives of Internal Medicine 1996; 156(7)731–739
   PubMed Web of Science ®Google Scholar
• Wright J.C., Bass M.N., Cutress T., Lee M. The Cost-effectiveness of Fluoridating Water Supplies in New Zealand. Australian and New Zealand. Journal of Public Health 2001; 25(2)170–178
   Web of Science ®Google Scholar
• Joyce T., Corman H., Grossman M. A Cost-effectiveness Analysis of Strategies to Reduce Infant Mortality. Medical Care 1988; 26(4)348–360
   PubMed Web of Science ®Google Scholar
• Laupacis A.D., Feeny D., Detsky A.S., Tugwell P.X. How Attractive Does a New Technology Have to be to Warrant Adoption and Utilization? Tentative Guidelines for Using Clinical and Economic Evaluations. Canadian Medical Association Journal 1992; 146(4)473–481
   PubMed Web of Science ®Google Scholar
• Murphy K.M., Topol R. The Economic Value of Medical Knowledge. University of Chicago 2001, http://gsbwww.uchicago.edu/fac/kevin.murphy/teaching/medicalknowledge.pdf. (accessed July 2002)
   Google Scholar
• Drummond J., Torrance G., Mason G. Cost-effectiveness League Tables: More Harm than Good?. Social Science and Medicine 1993; 37(1)33–40
   PubMed Web of Science ®Google Scholar
• Mason J., Drummond M., Torrance G. Some Guidelines on the Use of Cost Effectiveness League Tables. British Medical Journal 1993; 306(6877)570–572
   PubMed Web of Science ®Google Scholar
• Szucs T.D. Pharmaco-economic Aspects of Lipid-lowering Therapy: Is it Worth the Price?. European Heart Journal 1998; 19(Supplement M)M22–M28
   PubMedGoogle Scholar
• Farmer J.A. Economic Implications of Lipid-lowering Trials: Current Considerations in Selecting a Statin. American Journal of Cardiology 1998; 82(6A)26M–31M
   PubMedGoogle Scholar
• Cramer J.A., Spilker B. Quality of Life and Pharmacoeconomics: An Introduction. Lippincott-Raven Publishers, Philadelphia, PA 1998; 1–274
   Google Scholar
• Berger M. Willingness to Pay Versus Willingness to Buy: What Defines Value in Healthcare?. Value Health 1998; 1(4)201–203
   PubMedGoogle Scholar
• Tengs T.O., Graham J.D. The Opportunity Costs of Haphazard Social Investments in Life-saving. Risks, Costs, and Lives Saved: Getting Better Results from Regulation, R.W. Hahn. Oxford University Press, Washington, DC 1996; 182–197
   Google Scholar
• Wright A.T. Successful Management of Lipid-lowering Programs. Managed Care 2001; 10(11)10–11, (Supplement)
   Google Scholar
• Buchmueller T.C., Feldstein P.J. Consumers' Sensitivity to Health Plan Premiums: Evidence from a Natural Experiment in California. Health Affairs 1996; 15(1)143–151
   Web of Science ®Google Scholar
• John J. Perceived Quality in Health Care Service Consumption: What are the Structural Dimensions?. Developments in Marketing Science, J.M. Hawes, J. Thanopoulos. Academy of Marketing Science, Akron, OH 1989; 12: 518–521
   Google Scholar
• U. S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2, Williams & Wilkins, Baltimore, MD 1996; 953
   Google Scholar
• Wang L.Y., Haddix A.C., Teutsch S.M., Caldwell B. The Role of Resource Allocation Models in Selecting Clinical Preventive Services. American Journal of Managed Care 1999; 5(4)445–454
   PubMed Web of Science ®Google Scholar
• McKenney J.M. The Cost of Treating Dyslipidsemia Using National Cholesterol Education Program (NCEP) Guidelines. Pharmacoeconomics 1998; 14(3)19–28
   PubMedGoogle Scholar
• Law M.R., Wald N.J., Wu T., Hackshaw A., Bailey A. Systematic Underestimation of Association Between Serum Cholesterol and Ischaemic Heart Disease in Observational Studies: Data from the BUPA Study. British Medical Journal 1994; 308(6925)363–366
   PubMed Web of Science ®Google Scholar
• Law M.R., Wald N.J., Thompson S.M. By How Much and How Quickly Does Reduction in Serum Cholesterol Concentration Lower Risk of Ischaemic Heart Disease?. British Medical Journal 1994; 308(6925)367–373
   PubMed Web of Science ®Google Scholar
• Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease. Journal of the American Medical Association 1984; 251(3)351–364
   PubMed Web of Science ®Google Scholar
• Manninen V., Elo M.O., Frick M.H., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitanierni P., Koskinen P., Mäenpää H., Mälkönen M., Mänttäri M., Norola S., Pasternack A., Pikkarainen J., Romo M., Sjoblom T., Nikkitä E.A. Lipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart Study. Journal of the American Medical Association 1988; 260(5)641–651
   PubMed Web of Science ®Google Scholar
• Hay J.W., Yu W.M., Ashraf T. Pharmacoeconomics of Lipid-lowering Agents for Primary and Secondary Prevention of Coronary Heart Disease. Pharmacoeconomics 1999; 15(1)47–74
   PubMed Web of Science ®Google Scholar
• Scussa F. On Its Way to $10 Billion. MedAdNews 2002; 21(5)62–64, 1
   Google Scholar
• Jacobson T.A., Schein J.R., Williamson A., Ballantyne C.M. Maximizing the Cost-effectiveness of Lipid-lowering Therapy. Archives of Internal Medicine 1998; 158: 1977–1989
   PubMed Web of Science ®Google Scholar
• Goldstein J.L., Brown M.S. Regulation of the Mevalonate Pathway. Nature 1990; 343: 425–430
   PubMed Web of Science ®Google Scholar
• Auer J., Eber B.A. Clinical Focus on Statins. Current Opinion Investigational Drugs 2001; 2(3)382–388
   PubMedGoogle Scholar
• Rauch U., Osendle J.I., Chesebro J.H., Fuster V., Vorchheimer D.A., Harris K., Harris P., Sandler D.A., Fallon J.T., Jayaraman S., Badimon J.J. Statins and Cardiovascular Diseases: The Multiple Effects of Lipid-lowering Therapy. Atherosclerosis 2000; 153(1)181–189
   PubMed Web of Science ®Google Scholar
• Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Parkard C.J. For the West of Scotland Coronary Prevention Study Group. Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesteremia. New England Journal of Medicine 1995; 333(20)1301–1307
   PubMed Web of Science ®Google Scholar
• Sacks F.M., Pfeffer M.A., Moyé L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. For the Cholesterol and Recent Events Trial Investigators. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. New England Journal of Medicine 1996; 335(14)1001–1009
   PubMed Web of Science ®Google Scholar
• Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M., Jr. For the AFCAPS/TexCAPS Research Group. Primary Prevention of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels. Results of the AFCAPS/TexCAPS. Journal of the American Medical Association 1998; 279(20)1615–1622
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomized Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: the Scandinavian Simvastatin Survival Study(4 S). Lancet 1994; 344: 1383–1389
   PubMed Web of Science ®Google Scholar
• Gould A.L., Rossouw J.E., Santanello N.C., Heyes J.F., Furberg C.D. Cholesterol Reduction Yields Clinical Benefit: Impact of Statin Trials. Circulation 1998; 97(10)946–952
   PubMed Web of Science ®Google Scholar
• Holme I. Relationship between Total Mortality and Cholesterol Reduction as Found by Meta-regression Analysis of Randomized Cholesterol-lowering Trails. Controlled Clinical Trials 1996; 17(1)13–22
   PubMedGoogle Scholar
• Law M.R. Lowering Heart Disease Risk with Cholesterol Reduction: Evidence from Observational Studies and Clinical Trials. European Heart Journal 1999; 1(S)S3–S8
   Web of Science ®Google Scholar
• Jacobson T.A. Clinical Context: Current Concepts of Coronary Heart Disease Management. American Journal of Medicine 2001; 110(6)3S–11S
   PubMedGoogle Scholar
• Kashyap M. Clinical Aspects of Dyslipidemia. Managed Care 2001; 10(11)4–9, (Supplement)
   Google Scholar
• Stone N.J. Lipid Management: Current Diet and Drug Treatment Options. American Journal of Medicine 1996; 101(4A)40S–39S
   PubMedGoogle Scholar
• Maron D.J., Eazio S., Linton M.F. Current Perspectives on Statins. Circulation 2000; 101(2)207–213
   PubMed Web of Science ®Google Scholar
• Bazalo G.R. Managed Care Trends in Statin Usage. Managed Care 2001; 10(10)48–59
   Google Scholar
• Vogel R., Schaefer E. Should All Patients with Cardiovascular Disease Receive Statin Therapy?. American Journal of Managed Care 2001; 7(5)S117–S124
   PubMed Web of Science ®Google Scholar
• Howard P. Squeezing into the Statin Market. MedAdNews 2002; 21(5)3, 72
   Google Scholar
• Another Variation on a Tried and True Drug. MedAdNews 2002; 21(5)72
   Google Scholar
• Scussa F. Changes at the Top. MedAdNews 2002b; 21(5)1, 46, 48
   Google Scholar
• Sempos C.T., Cleeman J.I., Carroll M.D., Johnson C.I., Bachorik P.S., Gordon D.J., Burt V.L., Briefel R.R., Brown C.D., Lippel K., Rifkind B.M. Prevalence of High Blood Cholesterol Among US Adults: An Update Based on Guidelines from the Second Report of the National Cholesterol Education Program Adult Treatment Panel. Journal of the American Medical Association 1993; 269(23)3009–3014
   Web of Science ®Google Scholar
• NCEP Issues Major New Cholesterol Guidelines [press release]. National Institutes of Health, May 15, 2001.
   Google Scholar
• Manning R., Keith A. The Economics of Direct-to-Consumer Advertising of Prescription Drugs. Economic Realities in Health Care Policy 2001; 2(1)3–9
   Google Scholar
• Hoerger T.J., Bala M.V., Bray J.W., Wilcosky T.C., LaRosa J. Treatment Patterns and Distribution of Low-density Lipoprotein Cholesterol Levels in Treatment-eligible United States Adults. American Journal of Cardiology 1998; 82(1)61–65
   PubMed Web of Science ®Google Scholar
• Aggressive Cholesterol Lowering Reduces Atherosclerosis Progression in Bypass Graphs. NIH News Release, January 15,1997 www.nih.gov/news/pr/jan97/nhlbi-15.htm (Accessed July 2002).
   Google Scholar
• Marcelino J.J., Feingold K.B. Inadequate Treatment with HMG-CoA Reductase Inhibitors by Health Care Providers. American Journal of Medicine 1996; 100(6)605–610
   PubMed Web of Science ®Google Scholar
• Pearson T.A., Laurora I.M. Treatment Success in Patient Subgroups in the Lipid Treatment Assessment Project (L-TAP). Circulation 1997; 96(Supplement I)I–66
   Google Scholar
• Jackson G. The Role of Statins in Acute Coronary Syndromes: Managing the Unmet Need. International Journal of Clinical Practice 2000; 54(7)445–449
   PubMed Web of Science ®Google Scholar
• Goff C.V. An Employer Coalition to Reduce Costs and Improve Adherence. Managed Care 2001; 10(11)14–16, (Supplement)
   Google Scholar
• LaRosa J.C., He J., Vupputuri S. Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials. Journal of the American Medical Association 1999; 282(24)2508–2509
   Google Scholar
• Crouse J.R., Byington R.P., Hoen H.M., Furberg C.D. Reductase Inhibitor Monotherapy and Stroke Prevention. Archives of Internal Medicine 1997; 157: 1305–1310
   PubMed Web of Science ®Google Scholar
• Durrington P.N. Can We Afford to Treat Hyperlipidaemia as We Should? Strategies for Rational Treatment. Atherosclerosis 1998; 139(Supplement 1)S1–S5
   PubMedGoogle Scholar
• Johnson N.E. Trends in Pharmacoeconomic Outcomes Analyses. The Role of Pharmacoeconomics in Outcomes Management, N.E. Johnson, D.B. Nash. American Hospital Publishing, Inc. 1996; 85–93
   Google Scholar
• Latts L.M. Assessing the Results: Phase 1 Hyperlipidemia Outcomes in 27 Health Plans. American Journal of Medicine 2001; 110(6 A)17S–23S
   PubMedGoogle Scholar
• Ganz D.A., Juntz K.M., Jacobson G.A., Avorn J. Cost-effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapies in Older Patients with Myocardial Infarction. Archives of Internal Medicine 2000; 132(10)780–797
   Web of Science ®Google Scholar
• Huse D.M., Russell M.W., Miller J.D., Kraemer D.F., D'Agostino R.B., Ellison R.C., Hartz S.C. Cost-effectiveness of Statins. American Journal of Cardiology 1998; 82(11)1357–1363
   PubMed Web of Science ®Google Scholar
• Grover S.A., Coupal L., Paquet S., Zowall H. Cost-effectiveness of 3-hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors in the Secondary Prevention of Cardiovascular Disease. Archives of Internal Medicine 1999; 159(6)593–600
   PubMed Web of Science ®Google Scholar
• Pickin D.M., McCabe C.J., Ramsay L.E., Payne N., Haq I.U., Yeo W.W., Jackson P.R. Cost Effectiveness of HMG-CoA Reductase Inhibitor (Statin) Treatment Related to the Risk of Coronary Heart Disease and Cost of Drug Treatment. Heart 1999; 82(3)325–332
   PubMed Web of Science ®Google Scholar
• McMurray M. The Health Economics of the Treatment of Hyperlipidemia and Hypertension. American Journal of Hypertension 1999; 12(10 Part 2)99S–104S
   PubMed Web of Science ®Google Scholar
• Cobos A., Jovell A.J., Barcia-Altes A., Garcia-Closas R., Serra-Majem L. Which Statin is Most Efficient for the Treatment of Hypercholesterolemia? A Cost-effectiveness Analysis. Clinical Therapeutics 1999; 21(11)1924–1936
   PubMed Web of Science ®Google Scholar
• Reckless J.P. Cost Effectiveness in Statins. Current Opinion in Lipidology 2000; 11(4)351–356
   PubMed Web of Science ®Google Scholar
• Hilleman D.E., Wurdeman R.L., Lenz T.L. Therapeutic Change of HMG-CoA Reductase Inhibitors in Patients with Coronary Artery Disease. Pharmacotherapy 2001; 21(4)410–415
   PubMed Web of Science ®Google Scholar
• Maclaine G.D.H., Patel H.A. Cost-effectiveness Model of Alternative Statins to Achieve Target LDL-Cholesterol Levels. International Journal of Clinical Practice 2001; 55(4)243–249
   PubMed Web of Science ®Google Scholar
• Weinstein M.C., Stason W.B. Foundations of Cost-effectiveness Analysis for Health and Medical Practices. New England Journal of Medicine 1977; 296(13)716–721
   PubMed Web of Science ®Google Scholar
• Kupersmith J., Helmes-Rovner M., Hogan A., Rovner D., Gardiner J. Cost-effectiveness Analysis in Heart Disease. Part I: General Principles. Progress Cardiovascular Disease 1994; 37(3)161–184
   PubMed Web of Science ®Google Scholar
• Kmietowicz Z. UK Review Finds Statins are Cost Effective in Secondary Prevention British Medical Journal 1999; 319(7222)1390
   Google Scholar
• van Hout B.A., Simoons M.L. Cost-effectiveness of HMG Coenzyme Reductase Inhibitors: Whom to Treat?. European Heart Journal 2001; 22(9)751–761
   PubMed Web of Science ®Google Scholar